[Diabetic neuropathy].
Yagihashi
Soroku
S
Department of Pathology, Hirosaki University School of Medicine.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D002491:Central Nervous System Agents / Q000627:therapeutic use; D016207:Cytokines; D003929:Diabetic Neuropathies / Q000175:diagnosis / Q000209:etiology / Q000473:pathology / Q000628:therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000150:complications; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D009412:Nerve Fibers / Q000473:pathology; D018384:Oxidative Stress; D010525:Peripheral Nerves / Q000473:pathology; D011108:Polymers / Q000378:metabolism; D011379:Prognosis
D002491:Central Nervous System Agents; D016207:Cytokines; D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D011108:Polymers; C024617:polyol; D000449:Aldehyde Reductase